News
FDA approves Merck RSV monoclonal antibody shot for infants
Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in newborns and infants entering their first RSV season.
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more
Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback